drugset / Trial / NCT04117477

Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients

NCT04117477

Phase 2 Terminated 46 enrolled Children's Hospital Medical Center, Cincinnati
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The central hypothesis is that daily dental xylitol wipes, in addition to current oral care practice, are effective at reducing BSI from oral organisms, and decreasing the incidence of gingivitis, oral plaque, and oral ulcerations after SCT.

Timeline

Start
2019-09-27
Primary completion
2021-03-20
Completion
2021-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Xylitol Small molecule